SBC / revenue
Share-based compensation divided by revenue.
How it is calculated
Calculated as sbc / revenue, from Stock-based compensation, Revenue. A figure the company reported directly always outranks this calculation, and it is withheld when its inputs come from different filing vintages.
Highest reported
| Company | SBC / revenue | Period end |
|---|---|---|
| ASBP Aspire Biopharma Holdings, Inc. | 227849.9% | 2025-12-31 |
| BLNC Balance Labs, Inc. | 211673.3% | 2025-12-31 |
| LOTT Techlott Inc. | 196862.5% | 2025-12-31 |
| HODO House of Doge Inc. | 171205.7% | 2024-12-31 |
| MYSE Myseum.AI, Inc. | 134673.5% | 2025-12-31 |
| LYEL Lyell Immunopharma, Inc. | 116191.7% | 2025-12-31 |
| HCMC Healthier Choices Management Corp. | 113982.1% | 2025-12-31 |
| IPSI Innovative Payment Solutions, Inc. | 92160.0% | 2023-12-31 |
| NTHI NEONC TECHNOLOGIES HOLDINGS, INC. | 88909.9% | 2025-12-31 |
| RPMT REGO PAYMENT ARCHITECTURES, INC. | 87837.8% | 2025-12-31 |
| ACHR Archer Aviation Inc. | 74500.0% | 2025-12-31 |
| GNLX GENELUX Corp | 73387.5% | 2025-12-31 |
| ALT Altimmune, Inc. | 39209.8% | 2025-12-31 |
| HSCS HeartSciences Inc. | 30386.3% | 2026-04-30 |
| GFLT GenFlat Holdings, Inc. | 30216.8% | 2025-06-30 |
Latest annual period for each company; fiscal year ends differ. Figures are the filers’ own.
Every figure on this site links to the filing it came from. See the methodology for how periods and concepts are chosen, and the disclosures for what the data is not.